

Control oligo
LSA oligos
HeLa cells
C42B cells
LNCAP cells
U2OS cells
MDA MB231 cells
H460 cells

FIGURE 1



Ctrl
In2E2
In3E3
E3E4
ATG
mix
PARP
Cleaved PARP
HeLa cells
hSSB1
Actin
Untr
Ctrl
In3E3
In2E2
ATG
E3E4
Cleaved PARP
U2OS cells
γH2AX
hSSB1

FIGURE 2



Ctrl
In2LSA
In3LSA
E3LSA
ATGLSA
Untransf.
In2ASO
In3ASO
E3ASO
ATGASO
GFP
PARP
hSSB1
γH2Ax
Actin

FIGURE 3





Capan$
H460
Panc-1
A549
Hela
U2OS
LNCAP-C42B
Cell Growth (% confluence)
Time (hrs)
Drug
Control

FIGURE 4


A
Thoc4-In3
Thoc4-NegC
0nM
0nM
0.1nM
0.3nM
1nM
3nM
8nM
25nM
74nM
222nM
667nM
2000nM
B
hSSB1-In3
hSSB1-NegC


0nM
0nM
0.1nM
0.3nM
1nM
3nM
8nM
25nM
74nM
222nM
667nM
2000nM



C
Thoc4'EMSA''
Thoc'In3''
Thoc'NegC''
Percent'Oligo'bound'to'protein'
Conc'Protein'
hSSB1'EMSA'
SSB'In3''
SSB'NegC''
Percent'Oligo'bound'to'protein'
Conc'Protein'

FIGURE 5



GFP expression assay HeLa-BCl2 cells
CELL FLUORESCENCE INTENSITY
12,000
10,000
8,000
6,000
4,000
2,000
-
ATGLSA
IN3LSA
IN3LSA_CU
IN3LSA SCR_3_5
IN3LSA 50 nM
IN3LSA_CT4
IN3LSA_CT5
OPEN_ASO1
OPEN_LSA1
LACZ
LUC_2243
CDCA3_ASO_IN4E4
CDCA3_ASO_IN2E2
CDACA_ASO_ATG
CDCA3_LSA_IN4E4
CDCA3_LSA_IN2E2
CDCA3_LSA_ATG
CTRL
NEG C
NEGC_GAP
NEG C (50nM)
GFP
GFP

FIGURE 6




FIGURE 7




FIGURE 8





FIGURE 9



ANOVA, α = 0.05, comparison to ctrl

FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13



Tumour
Pre Injection
MA20140605093650_002A
Day 5
MA20140610144255_002A
Excised tumour
(Day 8)
MA20140613151423_002A
2.5
2.0
1.5
1.0
0.5
Radiant Efficiency
Color Scale
Max = 2.94e10

FIGURE 14




FIGURE 15






FIGURE 16

A



B



C

Molecule binding energy

Molecule	Binding energy (KJ/mol)	Stdev
ATGLSA	-2655.94	140.50
ATGLSA - Nucleotide	-3237.62	110.45
NEGC	-3177.35	140.09
NEGC - Nucleotide	-3322.67	162.01

D




FIGURE 17



Tumour volume change (%)
2000
1500
1000
500
0
PBS
ATG
****
0
5
10
15
20
25
30
35
Time (days)

FIGURE 18



PBS
ATG
Before treatment
Day 16
A
B
C
D
E
F
Luminescence
5 0
4 0
3 0
x10^8
2 0
1 0
Radiance
(p/sec/cm²/sr)
Color Scale
Min = 3.00e6
Max = 5.00e8

FIGURE 19




FIGURE 20




FIGURE 21




FIGURE 22



PBS
ATG
Before treatment
Day 18
A
B
C
D
E
F
Luminescence
1.5
1.0
0.5
x10^8
Radiance
(p/sec/cm²/sr)
Color Scale
Min = 7.00e5
Max = 1.50e8

FIGURE 23



120
100
80
60
40
20
0
Weight variation (%)
0
5
10
15
20
25
30
Time (days)
PBS
ATG

FIGURE 24




FIGURE 25




FIGURE 26




FIGURE 27




FIGURE 28